XenoPort Inc. (XNPT) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP raised its position in XenoPort Inc. (NASDAQ:XNPT) by 6.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,883,851 shares of the biopharmaceutical company’s stock after buying an additional 565,875 shares during the period. Wellington Management Group LLP owned approximately 14.04% of XenoPort worth $40,066,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of XNPT. Geode Capital Management LLC increased its stake in XenoPort by 1.6% in the first quarter. Geode Capital Management LLC now owns 389,911 shares of the biopharmaceutical company’s stock worth $1,758,000 after buying an additional 6,222 shares during the period. Royce & Associates LP boosted its position in XenoPort by 22.6% in the first quarter. Royce & Associates LP now owns 846,200 shares of the biopharmaceutical company’s stock worth $3,816,000 after buying an additional 156,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in XenoPort by 1.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,669,352 shares of the biopharmaceutical company’s stock worth $7,529,000 after buying an additional 17,505 shares in the last quarter. BlackRock Fund Advisors boosted its position in XenoPort by 1.2% in the first quarter. BlackRock Fund Advisors now owns 2,349,213 shares of the biopharmaceutical company’s stock worth $10,595,000 after buying an additional 27,788 shares in the last quarter. Finally, BlackRock Group LTD boosted its position in XenoPort by 30.2% in the first quarter. BlackRock Group LTD now owns 26,398 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 6,126 shares in the last quarter.

XenoPort Inc. (NASDAQ:XNPT) remained flat at $7.07 during trading on Tuesday. XenoPort Inc. has a 52 week low of $3.35 and a 52 week high of $7.86. The firm has a 50 day moving average of $6.71 and a 200 day moving average of $5.20.

XenoPort (NASDAQ:XNPT) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. The company earned $14.12 million during the quarter, compared to analyst estimates of $14.24 million. XenoPort’s quarterly revenue was up 99.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.33) earnings per share. On average, equities analysts anticipate that XenoPort Inc. will post ($0.49) earnings per share for the current year.

A number of research firms have weighed in on XNPT. Zacks Investment Research cut XenoPort from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Jefferies Group restated a “buy” rating on shares of XenoPort in a report on Tuesday, May 24th. Finally, Cowen and Company restated a “hold” rating on shares of XenoPort in a report on Friday, May 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. XenoPort presently has a consensus rating of “Hold” and a consensus price target of $6.44.

XenoPort, Inc is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders.